Wall Street analysts forecast that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will report ($0.52) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Bellicum Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.64). Bellicum Pharmaceuticals reported earnings per share of ($0.60) in the same quarter last year, which would suggest a positive year over year growth rate of 13.3%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full-year earnings of ($2.05) per share for the current year, with EPS estimates ranging from ($2.38) to ($1.72). For the next financial year, analysts expect that the business will post earnings of ($1.71) per share, with EPS estimates ranging from ($2.06) to ($1.37). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.83) by $0.28. The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.20 million. Bellicum Pharmaceuticals had a negative net margin of 6,729.02% and a negative return on equity of 123.00%.
NASDAQ BLCM traded down $0.03 during trading on Friday, reaching $1.93. 703,072 shares of the stock traded hands, compared to its average volume of 434,796. The stock has a market cap of $92.94 million, a P/E ratio of -0.78 and a beta of 1.72. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.74 and a current ratio of 4.74. Bellicum Pharmaceuticals has a fifty-two week low of $1.54 and a fifty-two week high of $10.26.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Bellicum Pharmaceuticals by 1.2% during the third quarter. Vanguard Group Inc. now owns 1,947,842 shares of the biopharmaceutical company’s stock worth $11,999,000 after acquiring an additional 23,410 shares in the last quarter. Rhumbline Advisers raised its position in Bellicum Pharmaceuticals by 349.3% during the fourth quarter. Rhumbline Advisers now owns 164,060 shares of the biopharmaceutical company’s stock worth $479,000 after acquiring an additional 127,543 shares in the last quarter. JPMorgan Chase & Co. raised its position in Bellicum Pharmaceuticals by 8.4% during the third quarter. JPMorgan Chase & Co. now owns 3,874,395 shares of the biopharmaceutical company’s stock worth $23,866,000 after acquiring an additional 300,816 shares in the last quarter. Knott David M raised its position in Bellicum Pharmaceuticals by 23.4% during the fourth quarter. Knott David M now owns 111,427 shares of the biopharmaceutical company’s stock worth $325,000 after acquiring an additional 21,100 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Bellicum Pharmaceuticals by 19.9% in the fourth quarter. Geode Capital Management LLC now owns 509,310 shares of the biopharmaceutical company’s stock valued at $1,487,000 after purchasing an additional 84,517 shares during the period. 54.90% of the stock is currently owned by hedge funds and other institutional investors.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.
Featured Story: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.